We have over 40 years of finding solutions for companies like you.

Sean Robbins has more than 20 years of experience in pricing and reimbursement in the pharmaceutical industry.

He has launched several products globally; and developed pricing and market access strategies for pharmaceutical products across the lifecycle. Most recently, he has developed strategies; and has been the primary lead for execution for the reimbursement for more than 15 ODD products in EU. He has been a thought leader in developing strategies and tactics to combat International Reference Pricing; and providing advice to companies about what they can do to better prepare for reference pricing.

He is the author of several publications in clinical and health economics journals; and has been involved in the development of pricing defence strategies for several of the early biosimilars launched in Europe. He was one of the only early advocates in pharma to institute value-based selling programs with “the field”; bringing Pricing Function and Key Account Management teams closer together to fostering shared goals in pricing execution. Sean is currently an Adjunct Professor at the University of Southern California in the Titus School of Pharmacy and Health Policy where he teaches pharmaceutical pricing and reimbursement. Sean is passionate about introducing profit enhancing pricing analytics and novel market access strategies into pharmaceutical companies to help drive improvements in company’s bottom line.

Ted joined LatticePoint in July 2016 and provides advisory services to early-stage companies in the cell and gene therapy space and has advised on market access, EMA Adaptive Pathways, international expansion, talent acquisition, and key customer relationships.

Prior to consulting, he spent 17 years working in the pharmaceutical industry and headed the Market Access function for Genzyme’s Rare Disease Business Unit and Pfizer’s Head of Head of Market Access, Primary Care BU. Before joining Pfizer, he spent 7 years at Schering-Plough in various regional and affiliate finance roles.

Ted began his career at Deloitte & Touche, including two years in Frankfurt, Germany and is a qualified SEC Audit Committee Financial Expert.

He is a frequent speaker on gene therapy pricing and has published on reforming payment for cell and gene therapies with colleagues from the Alliance for Regenerative Medicine.

He has a BS degree in accounting from Villanova University, a Master of Arts in International Affairs from The Fletcher School of Law & Diplomacy at Tufts University, and an MBA from the Leonard N. Stern School of Business at New York University. He speaks fluent German in addition to his native English.

Jordi joined LatticePoint in  2024. He holds a PhD in Biomedicine from the Universitat Autonoma de Barcelona, Spain and an executive MBA from ESADE law and business school.

He has been involved in +30 strategy and M&A projects. He has specialized in biotech and pharma companies, as well as CDMOs. He has worked for public and private companies, listed in EU and US, as well as Fortune500 companies and biotech unicorns. He has worked in different drug modalities, being very active in nuclear medicine and advanced therapy space.

He has more than 10 years of experience in scientific research, with a bachelor in biotechnology and a master in neuroscience. He obtained his PhD in 2016 at the CRG. After his postdoctoral experience, Jordi started working as an entrepreneur in residence, he is an inventor and co-founder of a biotech developing novel RNA modifying compounds for the treatment of oncological malignancies.

In addition to his scientific and entrepreneurship experience, Jordi holds an executive MBA from ESADE, law and business school.

Jordi has been awarded several grants and prices, like La Caixa International PhD Fellowship program and CERCA Pioneer Price for his thesis, Caixa Impulse 2017, European Research Council Proof of Concept 2017, Industria del Coneixement Producte 2018, Worldwide Cancer Research UK, Caixa Impulse Consolidate 2021, and EIC Transition.

Ela joined LatticePoint in  2020. She holds a PhD in Biomedicine from the University of Barcelona, Spain.

Ela joined LatticePoint with the aim of using her scientific skill set to help tackle issues closer to patient’s bedside. At LatticePoint she translated her excitement about the multidimensional nature of market access field into support of market access strategy projects for different European healthcare systems. Ela performs primary and secondary research, develops value communication tools, and contributes to writing of reimbursement dossiers and scientific publications as well as development of health economic models. During her time at LatticePoint, she built knowledge in disease areas like oncology, infectious diseases, and autoimmune disorders, and explored the world of advanced medicine therapies. Ela appreciates strategy-oriented discussions and an environment that promotes growth.

Before transitioning into consulting, Ela was a scientist in molecular biophysics field. She obtained a PhD from the University of Barcelona in Spain. In her research she focused on a question – what can we understand about intrinsically disordered proteins to change their label from undruggable to druggable? Investigation of the question led to several publications leaving her ready for new challenges.

Johannes joined LatticePoint in 2023. He obtained an M.Sc. in physics from the RWTH Aachen University (Germany) and a PhD for work in medical physics at the European Organization for Nuclear Research (CERN), Switzerland, and RWTH Aachen University.

Johannes has more than 6 years of experience in R&D of medical devices, gained during his PhD and post-doc work. His research was based at CERN and focused on detector development for radiation therapy of cancer patients.

In addition, Johannes has 1.5 years of experience in a consulting company for regulatory affairs for medical devices, where he established regulatory pathways (mainly for the EU and the USA), defined clinical strategies, and performed and reviewed clinical evaluations for medical devices in the EU following MDR and MDD legislations.

Ignacio joined LatticePoint in 2024 as a strategy & management consultant. He has a strong background in Biomedical Sciences and Healthcare, with track record in both pharmaceuticals and medical devices.

With over 4 years of experience in strategy consulting, Ignacio began his journey as an analyst at Fenix Group International, providing competitive intelligence services to top-tier pharmaceutical companies. In January 2021, he transitioned to Alira Health, where he developed expertise in various therapeutic areas, including oncology, CNS, metabolic disorders and rare diseases. His role at Alira Health encompassed a broad range of strategy assignments (conducting 20+ projects), ranging from upstream corporate strategy to commercial due diligences.

Ignacio holds a double master’s degree in Bioengineering and Industrial Business Management, along with a bachelor’s degree in biomedical sciences from Universitat de Barcelona. During his early career in academia, he contributed to two research programs at the protein engineering department and toxicology division of Institut Químic de Sarrià and Universitat de Barcelona, respectively.

Overall, Ignacio considers himself as a passionate, results-oriented healthcare consultant with experience in providing strategic guidance to help clients achieve their business objectives.

Benedetta joined LatticePoint in 2022. She holds a M.Sc. in Pharmaceutical Chemistry from the University of Trieste (Italy) and a Marie-Curie joint PhD in Pharmaceutical Sciences between the University of Basel (Switzerland) and the University of Ljubljana (Slovenia).

In LatticePoint, Benedetta has been involved in several value-based indication evaluation and prioritization projects, assessing products’ values from scientific, clinical, and market potential perspectives. Understanding the indications and the competitive landscape, her goal is to support the development of clinical strategies and evidence-generation plans, ensuring the capture of the real unmet needs and evidence gaps.

She has experience in pricing and reimbursement strategies for different European countries, with specific expertise in market access in Italy. She is responsible for the payer panel database, with a large collection of key stakeholders ranging from payers, prescribers, and HTA advisors to medical key opinion leaders in the US, Europe, and parts of Asia.

Prior to consulting, Benedetta specialized in the field of medicinal chemistry. In particular, her projects were focused on the development of potential future drug candidates for the treatment of inflammatory diseases and antibiotic resistance.

Estelle is the consultant at latticePoint where she supports the development of pricing and market access strategies for innovative therapies across global and European markets. She works closely with client to translate complex clinical and economic evidence into clear actionable strategies that support successful market access.

At lattice point Estelle leads and contributes to a range of project workstreams including primary research with payer and key opinion leaders, development of value communication materials and synthesis of insight to inform strategic recommendations. She has experience across multiple therapeutic areas with a particular focus on oncology and rare disease supporting clients in addressing evolving payer expectation and navigating complex reimbursement environments

Estelle plays a key role in the development of deliverable such as objection handlers launch prioritization framework and Advisory Board materials ensuring they are scientifically robust and tailored to payer and stakeholder needs. She is also actively involved in client communication, contributing to discussion and helping shape and deliver clear, concise, and helpful recommendation to clients.

Prior to joining LatticePoint, Estelle work as a medical science liaison at HRA pharma and as a Research Associate at Op2Lysis, where she contributed to preclinical research and protocol development in neurovascular disease. Her academic work focused on thrombolysis and stroke, with the strong foundation in cellular and molecular biology she holds a master degrees in human biology from the university of Zurich and completed a  PhD at the university of Normandy in collaboration with Op2Lysis.

Agnes joined LatticePoint in 2023. Her educational foundation was laid at the Technical University of Munich in Germany, where she completed both her bachelor’s and master’s degrees in biochemistry. Her academic carrier continued at Utrecht University in the Netherlands, where she pursued her PhD.

Her research primarily revolved around the study of large biomolecular systems, with a special emphasis on the dynamic interactions of microtubules with microtubule-associated proteins. For example, Agnes studied the Tau protein which is associated with neurodegeneration and the MAP7 protein overexpressed in several cancers.

Martina joined LatticePoint in 2023. She holds a M.Sc. in Molecular Biology from the University of Padova (Italy) and a PhD in Molecular Biology from the University of Vienna (Austria).

Martina has a research background in immunology with a focus on the molecular regulation of the inflammatory response and on the role of innate immune cells in shaping the tumour microenvironment.

Sara Conde joined LatticePoint in 2024 and is based at the Barcelona office. She holds a PhD in Biomedicine from the University of Barcelona (UB).

Sara has a research background in Neurodegenerative diseases, with special focus on neural circuit modulation. She has authored several peered-reviewed publications and her work has also been presented at multiple international meetings, for which she has been awarded by the IBRO Travel Grant and the Spanish Society of Neurosciences.

Her academic background includes a Bachelor in Biomedical sciences from the UB, and a Master in Translational biomedical sciences from the Autonomous University of Barcelona.

Xavi joined LatticePoint in 2024. He holds a MSc in Chemical Engineering and a PhD in Materials Science and Engineering, both from Universitat Politècnica de Catalunya (Spain).

He has carried out research stages in Norway, Japan and Belgium, where he acquired a wide expertise in biopolymer science and tissue engineering. His PhD was focused on the development of implantable biomaterials tailored for bone cancer treatment. He explored different composite materials based on hydrogel-calcium phosphates, intended to be used as bone fillers after surgical resection of bone tumor. This research led to several publications and a co-authored patent. Consequently, he actively participated in different technology transfer activities, including exploring licensing opportunities or contributing to regulatory and intellectual property strategies.

At Lattice Point, he is responsible of conducting secondary research, collecting, and synthesizing data (clinical, scientific, financial), and participating in primary research interviews with payers and clinical experts.

Sergio de Hita Román joined LatticePoint in 2025 and is based at the Barcelona office. He holds a PhD in Oncology and Translational Medicine from the University of Salamanca (Spain) and a PhD in Genetics from the University of Bordeaux (France).

Sergio has a research background in Oncology, as he worked on KRAS-mutant non-small cell lung cancer (NSCLC) models and clinical data to understand disease mechanisms, resistance to small molecule inhibitors and cell signaling pathway modulation. During his academic career, he has accumulated international experience in a set of diverse scientific research projects including the development of genetically engineered models for the molecular understanding of several types of cancers, as well as the pre-clinical development of liquid biopsy and IVD solutions for pediatric brain tumors.

Mairi joined LatticePoint in 2025 and is based at the Barcelona office. She holds a PhD in Optical Medical Imaging with Innovation and Entrepreneurship Studies and a Masters in Environmental and Sustainable Chemistry, both from the University of Edinburgh (UK).

Her research background is varied across the fields of chemistry and biology but was later focused primarily on the physiology of the cortical collecting duct of the kidney, with the aim of characterising a subset of epithelial cells that display cellular plasticity, particularly in disease states.

Before joining LatticePoint, Mairi worked as a Project Manager at Inveniam Group in Barcelona, specialising in public funding and strategic consultancy for European BioTechs and in the Tech Transfer Office of the University of Edinburgh focusing on strategic partnerships in Digital Health.

Michaela joined LatticePoint`s Geneva Office as Research Associate in 2026. She holds a PhD in Molecular Biology from the University of Wuerzburg (Germany).

At LatticePoint Michaela gained experience on  early asset commercial potential to inform internal go/no go decision of a pharmaceutical company.

Michaela has a research background in translational oncology with a focus on protein stability in colorectal cancer and genetic engineered mouse models. During her postdoc she broadened her scientific expertise into stem cell biology incl induced pluripotent stem cells.

Núria joined LatticePoint in 2025. She holds a PhD in Biomedicine from the University of Barcelona and an MBA in the Pharmaceutical Industry from CESIF.

She has over twelve years of international experience in biomedical research, focusing on cancer epigenetics, infectious diseases, and advanced cellular and organ-on-a-chip models to better understand disease mechanisms and therapeutic responses. Núria has contributed to multidisciplinary R&D projects across Europe, Asia, and Africa, and supported the development of molecular diagnostics for neglected diseases.

She now applies her scientific expertise to market access, helping shape strategies that support the successful launch of therapies and ultimately improve patient access.

Andreas joined LatticePoint’s Barcelona Office as Research Associate in 2026. He holds a M.Sc in Chemistry from Heidelberg University (Germany) and did his PhD in Biophysics at the Max Planck Institute for Medical Research in Heidelberg (Germany).
Andreas has a research background in synthetic Biology with a focus on the effect of shape changes on molecular organization in synthetic cells, integrating both experimental data analysis and computational modelling, and quantum chemistry.